ATE389651T1 - Als inhibitoren von c-met geeignete pyrrolzusammensetzungen - Google Patents

Als inhibitoren von c-met geeignete pyrrolzusammensetzungen

Info

Publication number
ATE389651T1
ATE389651T1 AT04781443T AT04781443T ATE389651T1 AT E389651 T1 ATE389651 T1 AT E389651T1 AT 04781443 T AT04781443 T AT 04781443T AT 04781443 T AT04781443 T AT 04781443T AT E389651 T1 ATE389651 T1 AT E389651T1
Authority
AT
Austria
Prior art keywords
inhibitors
met
compositions suitable
compounds
pyrrole compositions
Prior art date
Application number
AT04781443T
Other languages
English (en)
Inventor
Alex Aronov
Upul Bandarage
David Lauffer
Ronald C Tomlinson
Original Assignee
Vertex Pharma
Li Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, Li Pan filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE389651T1 publication Critical patent/ATE389651T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04781443T 2003-08-15 2004-08-16 Als inhibitoren von c-met geeignete pyrrolzusammensetzungen ATE389651T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49553503P 2003-08-15 2003-08-15

Publications (1)

Publication Number Publication Date
ATE389651T1 true ATE389651T1 (de) 2008-04-15

Family

ID=34193321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04781443T ATE389651T1 (de) 2003-08-15 2004-08-16 Als inhibitoren von c-met geeignete pyrrolzusammensetzungen

Country Status (7)

Country Link
US (2) US20050101650A1 (de)
EP (1) EP1660487B1 (de)
AT (1) ATE389651T1 (de)
AU (1) AU2004264440B2 (de)
CA (1) CA2536470A1 (de)
DE (1) DE602004012578T2 (de)
WO (1) WO2005016920A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60122176T2 (de) * 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
ATE535520T1 (de) 2006-08-23 2011-12-15 Eisai R&D Man Co Ltd Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8648104B2 (en) 2007-05-25 2014-02-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-Met
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
EP2321433A2 (de) * 2008-08-29 2011-05-18 F. Hoffmann-La Roche AG Diagnostika und behandlungen für vegf-unabhängige tumoren
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP3122900A1 (de) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
AU2022225035A1 (en) 2021-02-24 2023-08-31 Insilico Medicine Ip Limited Analogs for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4783532B2 (ja) * 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
EP1207864A2 (de) * 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Zusammensetzungen verwendbar als inhibitoren von erk
DE60122176T2 (de) * 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6750239B2 (en) * 2001-08-03 2004-06-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2004264440A1 (en) 2005-02-24
EP1660487A1 (de) 2006-05-31
US20060173055A1 (en) 2006-08-03
US7314885B2 (en) 2008-01-01
EP1660487B1 (de) 2008-03-19
DE602004012578T2 (de) 2008-12-11
CA2536470A1 (en) 2005-02-24
US20050101650A1 (en) 2005-05-12
AU2004264440B2 (en) 2008-10-23
WO2005016920A1 (en) 2005-02-24
DE602004012578D1 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE493401T1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
TW200633980A (en) Pyridones useful as inhibitors of kinases
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
ATE542814T1 (de) Pyrazinkinaseinhibitoren
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties